Status:

COMPLETED

Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")

Lead Sponsor:

Indivior Inc.

Conditions:

Opioid Dependency

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Patients who admit to using buprenorphine by the intravenous route will be randomized to either Subutex or Suboxone and be followed up for 3 months to determine if there is less injection with Suboxon...

Eligibility Criteria

Inclusion

  • Male or female opioid-dependent outpatient aged 18 years or older,
  • Women of childbearing potential must have a negative urine pregnancy test result at the Inclusion Visit (test under supervision of the investigator or designee),
  • Women of childbearing potential must use an effective birth control method. Women of non-childbearing potential must be postmenopausal or must be surgically sterile (hysterectomy and/or bilateral oophorectomy),
  • On buprenorphine (Subutex® or generic buprenorphine) maintenance therapy at a minimum daily dose of 2 mg for at least 3 months prior to inclusion,
  • Declaring buprenorphine intravenous misuse at least four times/week and showing needle marks,
  • Willing to stop or reduce buprenorphine intravenous misuse,
  • Having received oral and written information about the trial, and provided written informed consent prior to admission to this trial.

Exclusion

  • Pregnancy or breast-feeding,
  • Contraindication or history of hypersensitivity to buprenorphine, naloxone or to any excipient of Suboxone® or Subutex®,
  • Any medical or psychiatric condition which in the opinion of the investigator would make participation difficult or unsafe,
  • Participating in another trial,
  • Patients in the exclusion period of the "Fichier National des personnes qui se prêtent à des recherches biomédicales" (National Index of persons participating in biomedical researches, or National Index of volunteers).

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2011

Estimated Enrollment :

270 Patients enrolled

Trial Details

Trial ID

NCT00955162

Start Date

August 1 2009

End Date

May 1 2011

Last Update

November 30 2012

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

Csst Antibes

Antibes, France

2

Hopital Paul Guiraud

Bagneux, France

3

Cssa Bizia

Bayonne, France

4

Centre Carreire , CH Charles Perrens

Bordeaux, France